Overview

Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy and safety of a three drug combination therapy of aponermin, pomalidomide, and dexamethasone in the treatment of relapsed or refractory multiple myeloma
Phase:
NA
Details
Lead Sponsor:
Peking University People's Hospital
Treatments:
Dexamethasone
pomalidomide